Neuroendocrine prostate cancer treated with multimodal examination and therapy: A case report.

Hara, Midori; Kira, Satoru; Kamiyama, Manabu; Ihara, Tatsuya; Sato, Takeshi; Mitsui, Takahiko

Hara, Midori; Kira, Satoru; Kamiyama, Manabu; Ihara, Tatsuya; Sato, Takeshi; Mitsui, Takahiko.

Afiliación

Hara M; Department of Urology, University of Yamanashi Graduate School of Medical Sciences, Chuo-city, Yamanashi, Japan.
Kira S; Department of Urology, University of Yamanashi Graduate School of Medical Sciences, Chuo-city, Yamanashi, Japan.
Kamiyama M; Department of Urology, Toranomon Hospital Kajigaya, Tokyo, Japan.
Ihara T; Department of Urology, University of Yamanashi Graduate School of Medical Sciences, Chuo-city, Yamanashi, Japan.
Sato T; Department of Urology, Fujiyoshida Municipal Hospital, Fujiyoshida-city, Yamanashi, Japan.
Mitsui T; Department of Urology, University of Yamanashi Graduate School of Medical Sciences, Chuo-city, Yamanashi, Japan.

Urol Case Rep ; 44: 102158, 2022 Sep.

Article en En | MEDLINE | ID: mdl-35846514

ABSTRACT

ABSTRACT

Neuroendocrine prostate cancer (NEPC) is rare, with short overall survival, and no established standard therapy. Therefore, the management of NEPC is often challenging. We report a case of a 63-year-old male diagnosed with NEPC and treated with multimodal examinations and therapies. Chemotherapy of cisplatin and etoposide for 6 months had a certain effect. However, his cancer progressed, and he took genetic screening exams. It revealed that his tumor mutational burden was high, and pembrolizumab was started. In this report, we suggested several new treatments.

Palabras clave

Neuroendocrine prostate cancer; Peptide receptor radionuclide therapy; Tumor mutational burden high

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google